Please wait



(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001104659-24-110566 0001953107 XXXXXXXX LIVE 3 Common Stock, $0.0001 par value per share 03/09/2026 false 0001736730 13463J101 CAMP4 THERAPEUTICS CORPORATION One Kendall Square Building 1400 West, 3rd Floor Cambridge MA 02139 James P. Boylan (332) 275-5551 Enavate Sciences 106 W 56th Street, 8th Floor New York NY 10019 0001953107 N Enavate Sciences GP, LLC AF N DE 0.00 2495562.00 0.00 2495562.00 2495562.00 N 4.8 OO 0002040426 N Everest Aggregator, LP WC N DE 0.00 2495562.00 0.00 2495562.00 2495562.00 N 4.8 PN Common Stock, $0.0001 par value per share CAMP4 THERAPEUTICS CORPORATION One Kendall Square Building 1400 West, 3rd Floor Cambridge MA 02139 This Amendment No. 3 (this "Amendment No. 3" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on October 22, 2024 and amended on September 15, 2025 and December 23, 2025 (as amended, the "Statement") by the Reporting Entities. Unless otherwise defined herein, capitalized terms used in this Amendment No. 3 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged. Rows 11 and 13 of each Reporting Entities' cover page to this Schedule 13D/A set forth the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by such Reporting Entity and are incorporated by reference. The percentage set forth in each row 13 is based upon 51,919,321 shares of Common Stock outstanding as of March 4, 2026, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on March 5, 2026. Everest LP directly holds 2,495,562 shares of Common Stock. Enavate GP is the general partner of Everest LP and shares voting and investment authority over the shares held by Everest LP. Rows 7 through 10 of each Reporting Entities' cover page to this Schedule 13D/A set forth the number of shares of Common Stock as to which such Reporting Entity has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference. Except as set forth below, none of the Reporting Entities has effected any transactions with respect to the securities of the Issuer during the past sixty days. On January 12, 2026, Everest LP sold an aggregate of 497 shares in open market transactions at prices ranging from $6.05 to $6.20 (weighted average sales price of $6.11 per share). On January 14, 2026, Everest LP sold an aggregate of 11,228 shares in open market transactions at prices ranging from $6.00 to $6.05 (weighted average sales price of $6.00 per share). On February 25, 2026, Everest LP sold an aggregate of 7,561 shares in open market transactions at prices ranging from $4.50 to $4.62 (weighted average sales price of $4.59 per share). On February 26, 2026, Everest LP sold an aggregate of 5,413 shares in open market transactions at prices ranging from $4.50 to $4.63 (weighted average sales price of $4.54 per share). On February 27, 2026, Everest LP sold an aggregate of 2,395 shares in open market transactions at prices ranging from $4.50 to $4.72 (weighted average sales price of $4.63 per share). On March 2, 2026, Everest LP sold an aggregate of 6,926 shares in open market transactions at prices ranging from $4.50 to $4.63 (weighted average sales price of $4.52 per share). On March 9, 2026, Everest LP sold an aggregate of 91,699 shares in open market transactions at prices ranging from $6.50 to $7.15 (weighted average sales price of $6.69 per share). On March 10, 2026, Everest LP sold an aggregate of 99,639 shares in open market transactions at prices ranging from $5.55 to $6.35 (weighted average sales price of $5.83 per share). No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Common Stock. The Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on March 9, 2026. Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Reporting Entities' Schedule 13D filed with the SEC on October 22, 2024). Enavate Sciences GP, LLC /s/ James P. Boylan By James P. Boylan, Manager 03/11/2026 Everest Aggregator, LP /s/ James P. Boylan By: Enavate Sciences GP, LLC, its General Partner, By James P. Boylan, Manager 03/11/2026